Ligence is a leading brand that specializes in the development of innovative solutions for medical diagnostics. With a focus on cardiovascular health, Ligence offers a range of products and services designed to improve patient outcomes. One of their notable projects is the development of a prototype for the diagnosis of heart damage caused by SARS-CoV-2 infection.

This project involves the application of deep learning neural networks in 2D transthoracic echocardiography (TTE) to assess heart complications often observed in COVID-19 patients. Through a clinical trial conducted in major Lithuanian hospitals, experienced cardiologists will label the images, which will be used to train deep learning algorithms. The aim is to create a tool that can automatically assess common COVID-19-related heart complications, such as myocarditis and acute heart failure, enabling better treatment planning and clinical decision-making.

Another project by Ligence focuses on the development of an automated system for the evaluation of left atrium myocardial strain indicators. This system, called LAstrain. AI, addresses a global problem in the assessment of left atrial myocardial deformation indicators.

The goal is to provide a new product on a global scale that will greatly reduce the dependency on researcher skills and experience, increase the accuracy of evaluations, and ultimately enhance healthcare efficiency. Ligence is dedicated to advancing medical diagnostics and improving patient care through cutting-edge technology